Chapter 18: Antiparkinson's Disease Drugs — Module 8: Drug-Induced Parkinsonism, Special Populations, and Integrated Practice Core Concepts — Foundational Knowledge (22 questions)
1. A 68-year-old woman with Parkinson's disease is admitted for elective cholecystectomy. The surgical team requests an antiemetic for postoperative nausea. Which of the following agents is most likely to worsen her parkinsonism and should be avoided?
A) Ondansetron
B) Metoclopramide
C) Rotigotine
D) Carbidopa
E) Ondansetron combined with dexamethasone
ANSWER: B
Rationale:
This question asked you to identify the agent most dangerous to a patient with Parkinson's disease in the perioperative antiemetic context. Option B is correct. Metoclopramide is a dopamine D2 receptor antagonist that crosses the blood-brain barrier and blocks nigrostriatal dopamine receptors, directly worsening parkinsonism in patients with Parkinson's disease. It is one of the most common drug-induced causes of parkinsonian exacerbation in clinical practice and is explicitly contraindicated in PD.
Option A: Option A is incorrect. Ondansetron blocks serotonin 5-HT3 receptors and has no dopamine receptor blocking activity; it is the preferred antiemetic for patients with Parkinson's disease.
Option C: Option C is incorrect. Rotigotine is a dopamine agonist delivered transdermally; it is a treatment for PD, not an antiemetic, and would not worsen parkinsonism.
Option D: Option D is incorrect. Carbidopa is a peripheral aromatic amino acid decarboxylase inhibitor used in combination with levodopa to reduce peripheral levodopa conversion; it is not an antiemetic and does not worsen parkinsonism.
Option E: Option E is incorrect. Ondansetron combined with dexamethasone is a commonly used antiemetic regimen in the perioperative setting; ondansetron carries no dopamine-blocking risk in PD.
2. A 72-year-old man develops bilateral bradykinesia, rigidity, and shuffling gait approximately three months after starting risperidone for behavioral disturbance. His neurologist orders a dopamine transporter (DAT) SPECT imaging study. Which result is most consistent with drug-induced parkinsonism rather than idiopathic Parkinson's disease?
A) Markedly reduced DAT binding bilaterally
B) Asymmetrically reduced DAT binding, worse on the right
C) Reduced DAT binding confined to the caudate nuclei
D) Normal DAT binding bilaterally
E) Absent DAT signal throughout the striatum
ANSWER: D
Rationale:
This question asked you to identify the expected DAT scan finding that distinguishes drug-induced parkinsonism from idiopathic Parkinson's disease. Option D is correct. In drug-induced parkinsonism (DIP), the nigrostriatal dopaminergic pathway is structurally intact — dopaminergic neurons have not been lost. The motor features result from pharmacological blockade of postsynaptic D2 receptors, not from presynaptic neuronal degeneration. Because the dopamine transporter is expressed on presynaptic dopaminergic terminals that remain structurally present, DAT imaging shows normal binding in DIP.
Option A: Option A is incorrect. Markedly reduced bilateral DAT binding indicates significant loss of presynaptic dopaminergic terminals, which is the hallmark of idiopathic Parkinson's disease, not DIP.
Option B: Option B is incorrect. Asymmetric DAT reduction is the classic pattern of early idiopathic PD, reflecting the characteristically asymmetric onset of neuronal degeneration; DIP is typically symmetric and produces a normal scan.
Option C: Option C is incorrect. Caudate-selective DAT reduction is associated with certain atypical parkinsonian syndromes but is not the expected finding in drug-induced parkinsonism, which produces a normal scan.
Option E: Option E is incorrect. Absent DAT signal throughout the striatum would represent near-complete nigrostriatal degeneration, inconsistent with drug-induced parkinsonism where neurons remain intact.
3. A 34-year-old woman with young-onset Parkinson's disease becomes pregnant. Her current regimen includes pramipexole and rasagiline. Her movement disorder specialist advises adjusting her medications during pregnancy. Which antiparkinson agent has the most pregnancy safety experience and is generally preferred when motor symptoms require ongoing pharmacological management during pregnancy?
A) Levodopa/carbidopa
B) Pramipexole
C) Rasagiline
D) Ropinirole
E) Amantadine
ANSWER: A
Rationale:
This question asked you to identify the antiparkinson agent with the most pregnancy safety data and the one generally preferred when treatment must be continued. Option A is correct. Levodopa has the longest human pregnancy experience of any antiparkinson agent. While animal studies have shown skeletal malformations at high doses, human case series have not demonstrated a consistent teratogenic signal at therapeutic doses. Movement disorder specialists generally recommend continuing levodopa/carbidopa when motor symptoms are severe enough to impair safe functioning, using the lowest effective dose. It is the safest available option relative to the alternatives.
Option B: Option B is incorrect. Pramipexole is a non-ergot dopamine agonist with limited human pregnancy data; it is classified based on preclinical toxicology findings and is generally avoided, particularly in the first trimester.
Option C: Option C is incorrect. Rasagiline is an MAO-B inhibitor with insufficient human pregnancy data; it is generally discontinued during pregnancy given the lack of safety information and theoretical risks.
Option D: Option D is incorrect. Ropinirole, like pramipexole, is a non-ergot dopamine agonist with limited human pregnancy data and is generally avoided in the first trimester and used only if the clinical need clearly outweighs the uncertainty.
Option E: Option E is incorrect. Amantadine is generally discontinued during pregnancy due to lack of safety data and theoretical fetal risks; it does not have a favorable pregnancy safety profile compared to levodopa.
4. A 75-year-old man with Parkinson's disease undergoes elective hip replacement. In the recovery room, he develops nausea. The anesthesiologist asks which antiemetic is safest to administer. Which of the following is correct regarding antiemetic selection in patients with Parkinson's disease?
A) Prochlorperazine is preferred because it is less sedating than other antiemetics
B) Metoclopramide is safe at low doses in PD patients with mild disease
C) Ondansetron is preferred because it has no dopamine receptor blocking activity
D) Promethazine is the agent of choice for PD-associated nausea
E) Droperidol is acceptable provided the dose is kept below 1.25 mg
ANSWER: C
Rationale:
This question asked you to identify the safest antiemetic choice in a patient with Parkinson's disease. Option C is correct. Ondansetron is a selective serotonin 5-HT3 receptor antagonist with no activity at dopamine receptors. Because it does not block D2 receptors, it does not worsen parkinsonism and is the preferred antiemetic for patients with PD in both the perioperative setting and for general nausea management.
Option A: Option A is incorrect. Prochlorperazine is a phenothiazine antipsychotic with potent D2 receptor blocking activity; it is contraindicated in Parkinson's disease because it will significantly worsen motor symptoms regardless of the sedation profile.
Option B: Option B is incorrect. Metoclopramide is a D2 receptor antagonist that is contraindicated in Parkinson's disease at any dose; there is no safe dose threshold for PD patients, as even low doses can cause clinically meaningful parkinsonian exacerbation.
Option D: Option D is incorrect. Promethazine is a phenothiazine with dopamine receptor blocking properties and significant anticholinergic activity; it is not appropriate for PD-associated nausea and can worsen both motor symptoms and cognitive function.
Option E: Option E is incorrect. Droperidol is a butyrophenone antipsychotic and potent D2 receptor antagonist; it is contraindicated in Parkinson's disease, and dose reduction does not eliminate the risk of motor worsening.
5. A 79-year-old man with advanced Parkinson's disease is scheduled for a six-hour abdominal surgery requiring a prolonged nil-by-mouth (NPO) period beginning at midnight. His current regimen includes levodopa/carbidopa every three hours during waking hours. Which strategy best maintains dopaminergic therapy continuity during the perioperative NPO period?
A) Withhold all antiparkinson medications until oral intake resumes postoperatively
B) Convert levodopa/carbidopa to a sustained-release formulation the evening before surgery
C) Administer levodopa/carbidopa via nasogastric tube intraoperatively
D) Start an intravenous dopamine infusion to substitute for oral levodopa during the NPO period
E) Apply a rotigotine transdermal patch to maintain basal dopaminergic tone through the NPO period
ANSWER: E
Rationale:
This question asked you to identify the best pharmacological strategy for maintaining dopaminergic continuity in a patient with Parkinson's disease during a prolonged nil-by-mouth period. Option E is correct. Rotigotine is a dopamine agonist available as a transdermal patch that delivers continuous drug absorption through the skin, bypassing the requirement for oral intake. It can be applied before surgery and maintained through the fasting period, providing basal dopaminergic tone without requiring gastrointestinal access. This is the established perioperative bridging strategy for patients with PD who cannot take oral medications.
Option A: Option A is incorrect. Withholding all antiparkinson medications is the most dangerous approach. Levodopa has a plasma half-life of approximately one hour, and motor and non-motor deterioration — including acute akinesia, aspiration risk, and rigidity — can develop within hours of drug withdrawal.
Option B: Option B is incorrect. Converting to sustained-release levodopa/carbidopa the evening before surgery does not solve the problem of NPO restriction during and after surgery; the patient still cannot take oral medications through the perioperative period.
Option C: Option C is incorrect. Nasogastric tube administration of levodopa intraoperatively is logistically complex, not standard practice, and carries risks related to tube placement; transdermal rotigotine is the established and preferred solution.
Option D: Option D is incorrect. Intravenous dopamine does not cross the blood-brain barrier and therefore provides no antiparkinson benefit; peripheral dopamine infusion cannot substitute for central dopaminergic therapy.
6. A surgical team asks why Parkinson's disease medications cannot simply be withheld on the morning of surgery along with other oral medications, as is standard practice for most drugs. Which pharmacokinetic property of levodopa best explains why even brief withholding carries clinical risk?
A) Levodopa has a half-life of 12 to 18 hours, producing gradual offset over days
B) Levodopa has a plasma half-life of approximately one hour, causing rapid loss of therapeutic effect
C) Levodopa is extensively protein-bound, prolonging its duration of action after a single dose
D) Levodopa undergoes zero-order elimination, making plasma levels unpredictable after dosing stops
E) Levodopa has a large volume of distribution, sustaining brain concentrations for six to eight hours after the last oral dose
ANSWER: B
Rationale:
This question asked you to identify the pharmacokinetic property of levodopa that makes even short periods of withholding clinically dangerous. Option B is correct. Levodopa has a plasma half-life of approximately one hour. This very short half-life means that plasma concentrations fall rapidly after the last oral dose, and the motor and non-motor consequences of levodopa withdrawal — including akinesia, rigidity, and aspiration risk — can manifest within hours of the last dose. This is why the perioperative period demands specific planning: standard NPO protocols that are appropriate for most medications are not safe for levodopa.
Option A: Option A is incorrect. A half-life of 12 to 18 hours would provide a much wider buffer against brief withholding; levodopa's actual half-life of approximately one hour is far shorter and does not allow for any meaningful grace period.
Option C: Option C is incorrect. Levodopa is minimally protein-bound; extensive protein binding would prolong its effect, but this does not describe levodopa's pharmacokinetic profile.
Option D: Option D is incorrect. Levodopa undergoes first-order elimination, not zero-order; zero-order kinetics apply to drugs like ethanol and describe a constant rate of elimination independent of concentration, which is not characteristic of levodopa.
Option E: Option E is incorrect. Levodopa does not have a large volume of distribution, and brain concentrations do not persist for six to eight hours after the last oral dose; the short half-life means that both plasma and brain concentrations fall rapidly.
7. A 65-year-old woman with schizophrenia has been on haloperidol for eight years. She now presents with bradykinesia, masked facies, and cogwheel rigidity. Her neurologist is trying to determine whether she has developed drug-induced parkinsonism or has underlying idiopathic Parkinson's disease that was unmasked. Which clinical feature, if present, would most favor drug-induced parkinsonism over idiopathic Parkinson's disease?
A) Resting tremor of the right hand with pill-rolling quality
B) Gradual onset of symptoms over twelve months
C) Progressive worsening despite dose reduction of haloperidol
D) Symmetric onset of bradykinesia and rigidity affecting both sides equally
E) Excellent response to a levodopa trial
ANSWER: D
Rationale:
This question asked you to identify the clinical feature that most favors drug-induced parkinsonism over idiopathic Parkinson's disease. Option D is correct. Drug-induced parkinsonism characteristically presents with bilateral, symmetric motor features — bradykinesia and rigidity affecting both sides at the same time. This reflects the pharmacological mechanism: systemic drug exposure produces diffuse bilateral D2 receptor blockade rather than the asymmetric, focal neuronal loss that characterizes idiopathic PD. Idiopathic Parkinson's disease is almost invariably asymmetric at onset, typically affecting one side first before gradual contralateral spread over years. Bilateral symmetric onset is therefore a strong clinical signal favoring DIP.
Option A: Option A is incorrect. A unilateral resting tremor with pill-rolling quality is a classic presentation of idiopathic Parkinson's disease; rest tremor is often absent in drug-induced parkinsonism, where postural or action tremors may predominate instead.
Option B: Option B is incorrect. A gradual onset over twelve months does not reliably discriminate between DIP and idiopathic PD; both conditions can develop insidiously, and this timeframe is not a distinguishing feature.
Option C: Option C is incorrect. Progressive worsening despite haloperidol dose reduction could suggest idiopathic PD being unmasked rather than drug-induced parkinsonism, which would be expected to stabilize or improve as the causative agent is reduced.
Option E: Option E is incorrect. A robust response to levodopa would favor idiopathic PD rather than DIP; in drug-induced parkinsonism, levodopa is generally not effective because the dopamine receptor is pharmacologically blocked by the offending drug, preventing levodopa from acting at its target.
8. A 74-year-old man presents with a two-year history of progressive right-hand tremor, bradykinesia, and stooped posture. Neurological examination confirms early Parkinson's disease with no cognitive impairment. He has mild chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 48 mL/min. Which antiparkinson regimen is most appropriate as initial monotherapy in this patient?
A) Levodopa/carbidopa
B) Pramipexole
C) Ropinirole
D) Rotigotine transdermal patch
E) Selegiline
ANSWER: A
Rationale:
This question asked you to identify the most appropriate initial antiparkinson monotherapy in an older adult with early PD and mild renal impairment. Option A is correct. Current guidelines recommend initiating antiparkinson therapy with levodopa/carbidopa rather than a dopamine agonist in patients over 70 years of age. Older adults are at significantly increased risk for dopamine agonist adverse effects — orthostatic hypotension, hallucinations, excessive daytime sleepiness, and impulse control disorders — due to age-related changes in autonomic reflexes, cholinergic reserve, and sleep architecture. Levodopa/carbidopa provides reliable efficacy with a more favorable adverse effect profile in this age group.
Option B: Option B is incorrect. Pramipexole is a dopamine agonist that is generally not preferred as initial monotherapy in patients over 70 due to the adverse effect profile described above; additionally, pramipexole requires renal dose adjustment in patients with reduced eGFR, which this patient has, adding further complexity.
Option C: Option C is incorrect. Ropinirole, like pramipexole, is a dopamine agonist that is not preferred for initial therapy in older adults; it also requires renal dose adjustment.
Option D: Option D is incorrect. Rotigotine transdermal is a dopamine agonist that may offer more stable plasma levels than oral agonists but still carries the class-wide adverse effect risks that make agonists less suitable as first-line agents in patients over 70.
Option E: Option E is incorrect. Selegiline, an MAO-B inhibitor, has mild symptomatic benefit in early PD but is generally insufficient as monotherapy for patients with established motor symptoms requiring treatment; it is not the preferred first-line agent when meaningful symptom control is needed.
9. A 31-year-old woman with young-onset Parkinson's disease delivers a healthy infant and wishes to breastfeed. Her neurologist explains that her current dopamine agonist therapy may interfere with breastfeeding. What is the primary mechanism by which dopamine agonists affect lactation?
A) Dopamine agonists increase oxytocin release, causing premature milk let-down
B) Dopamine agonists block prolactin receptors in mammary gland tissue
C) Dopamine agonists accelerate hepatic metabolism of estrogen, reducing lactogenesis
D) Dopamine agonists stimulate somatostatin release, which inhibits prolactin secretion
E) Dopamine agonists activate D2 receptors in the pituitary, suppressing prolactin secretion and reducing milk production
ANSWER: E
Rationale:
This question asked you to identify the mechanism by which dopamine agonists interfere with lactation. Option E is correct. Prolactin secretion from the anterior pituitary is normally under tonic inhibitory control by dopamine acting at D2 receptors on lactotroph cells. Dopamine agonists mimic this inhibitory dopaminergic signal, activating D2 receptors in the pituitary and suppressing prolactin release. Since prolactin is the primary hormonal driver of milk production, dopamine agonist therapy directly reduces milk supply. This mechanism is so reliable that bromocriptine, an ergot dopamine agonist, was historically used therapeutically to suppress lactation, though this use has been largely abandoned due to cardiovascular risks.
Option A: Option A is incorrect. Dopamine agonists do not increase oxytocin release; oxytocin mediates the milk let-down reflex but is not the primary target of dopamine agonist action on lactation.
Option B: Option B is incorrect. Dopamine agonists do not act on prolactin receptors in mammary tissue; their effect is entirely at the level of prolactin secretion in the anterior pituitary, not at the mammary gland receptor level.
Option C: Option C is incorrect. Dopamine agonists do not significantly affect hepatic estrogen metabolism or act through an estrogen-dependent mechanism to alter lactogenesis.
Option D: Option D is incorrect. Somatostatin is a growth hormone release-inhibiting hormone; it does not play a primary role in prolactin regulation, and dopamine agonists do not act through somatostatin to suppress prolactin.
10. A 58-year-old man with bipolar disorder and well-controlled epilepsy has been on valproic acid for four years. He now presents with a three-month history of bradykinesia, mild rigidity, and postural instability. Neurological examination is consistent with parkinsonism. DAT scan is normal. Which mechanism best explains valproic acid-induced parkinsonism?
A) Valproic acid blocks dopamine D2 receptors in the striatum
B) Valproic acid depletes presynaptic dopamine stores by inhibiting tyrosine hydroxylase
C) Valproic acid causes mitochondrial dysfunction in dopaminergic neurons
D) Valproic acid inhibits dopamine reuptake transporters, paradoxically depleting dopamine over time
E) Valproic acid increases GABA activity in the striatum, which directly inhibits dopaminergic pathways
ANSWER: C
Rationale:
This question asked you to identify the mechanism by which valproic acid produces a parkinsonian syndrome. Option C is correct. Valproic acid causes parkinsonism through a mechanism that is distinct from the dopamine receptor blockade responsible for antipsychotic-induced DIP. The prevailing explanation is that valproic acid impairs mitochondrial function in dopaminergic neurons, potentially through effects on mitochondrial oxidative phosphorylation and energy metabolism. This mitochondrial toxicity can reduce dopaminergic neuronal function without causing the structural neuronal loss that would reduce DAT binding, which is consistent with the normal DAT scan seen in this patient. The DAT scan finding here is important: it confirms that despite the parkinsonian clinical presentation, the presynaptic dopaminergic terminals are structurally intact, pointing away from idiopathic PD and toward a drug-induced mechanism.
Option A: Option A is incorrect. Valproic acid does not block dopamine D2 receptors; D2 receptor blockade is the mechanism of antipsychotic-induced and metoclopramide-induced DIP, not valproate-induced parkinsonism.
Option B: Option B is incorrect. Valproic acid does not deplete presynaptic dopamine by inhibiting tyrosine hydroxylase; this mechanism is responsible for the parkinsonism caused by reserpine and tetrabenazine, which deplete monoamine stores by blocking vesicular monoamine transporter 2 (VMAT2).
Option D: Option D is incorrect. Valproic acid does not inhibit the dopamine reuptake transporter; this is not a recognized mechanism of its action or its adverse effects.
Option E: Option E is incorrect. While valproic acid does enhance GABAergic transmission, this enhancement does not directly produce parkinsonism through a well-established inhibitory effect on dopaminergic pathways; the mitochondrial dysfunction mechanism is the accepted explanation.
11. A 77-year-old man with Parkinson's disease develops postoperative delirium following elective colectomy. The surgical resident proposes haloperidol 0.5 mg IV for agitation management. The attending physician intervenes. Which of the following best explains why haloperidol is contraindicated in this patient, and which agent would be a safer alternative?
A) Haloperidol causes QTc prolongation in PD patients specifically; lorazepam is the safer alternative
B) Haloperidol blocks D2 receptors, causing severe motor worsening in PD; quetiapine 12.5 to 25 mg is a safer alternative
C) Haloperidol interacts with levodopa to produce serotonin syndrome; olanzapine is the safer alternative
D) Haloperidol lowers the seizure threshold in PD patients; risperidone is the safer alternative
E) Haloperidol is safe in PD at doses below 1 mg; the concern is only at higher doses
ANSWER: B
Rationale:
This question asked you to identify why haloperidol is dangerous in Parkinson's disease and which agent can be used instead for delirium management. Option B is correct. Haloperidol is a potent D2 receptor antagonist. In a patient with Parkinson's disease, blocking D2 receptors in the striatum produces severe motor worsening — dramatically increasing rigidity, bradykinesia, and postural instability. The standard pharmacological approach to delirium management using haloperidol, which is appropriate in the general surgical population, is therefore contraindicated in PD. Low-dose quetiapine (12.5 to 25 mg) is the preferred agent when pharmacological management of delirium or agitation is necessary in a PD patient; quetiapine has very low D2 receptor affinity at clinical doses for psychiatric indications and is generally well tolerated in PD. Pimavanserin, a selective 5-HT2A inverse agonist, is another safe option.
Option A: Option A is incorrect. While haloperidol does carry QTc prolongation risk, this is not specific to PD patients and does not explain the primary contraindication; the motor worsening from D2 blockade is the critical concern, and lorazepam is not a preferred first-line agent for delirium management in PD.
Option C: Option C is incorrect. Haloperidol does not cause serotonin syndrome through an interaction with levodopa; serotonin syndrome is mediated by excess serotonergic activity, and haloperidol does not have this interaction profile with levodopa.
Option D: Option D is incorrect. Haloperidol does not specifically lower the seizure threshold in PD patients to a degree that constitutes the primary contraindication; D2 receptor blockade with resulting motor deterioration is the core problem.
Option E: Option E is incorrect. There is no safe dose of haloperidol in Parkinson's disease; even low doses can cause clinically significant worsening of motor symptoms and should be avoided entirely.
12. A 71-year-old woman with Parkinson's disease reports that her levodopa seems to work well in the morning but loses its effect after lunch. Her neurologist notes she typically eats a high-protein lunch. Which mechanism best explains this meal-related wearing-off pattern?
A) High-fat meals delay gastric emptying and reduce the rate of levodopa absorption from the small intestine
B) Dietary protein activates hepatic CYP enzymes, accelerating levodopa metabolism and reducing bioavailability
C) Protein-rich meals increase peripheral AADC activity, converting more levodopa to dopamine before it reaches the brain
D) Dietary amino acids compete with levodopa for the large neutral amino acid transporter, reducing uptake across the gut and blood-brain barrier
E) High-protein meals raise gastric pH, which impairs levodopa dissolution and absorption
ANSWER: D
Rationale:
This question asked you to identify the mechanism by which dietary protein reduces levodopa efficacy. Option D is correct. Levodopa is a large neutral amino acid and is transported across both the intestinal epithelium and the blood-brain barrier by the large neutral amino acid (LNAA) transporter — the same transporter used by dietary amino acids from protein digestion including phenylalanine, tyrosine, leucine, isoleucine, and valine. When a high-protein meal floods the bloodstream with these competing amino acids, they compete with levodopa for LNAA transporter access at both absorption sites, reducing both gut absorption and brain uptake of levodopa. This produces the characteristic post-meal motor wearing-off seen in this patient. A practical management strategy is protein redistribution — concentrating the day's protein intake in the evening meal while keeping daytime meals low in protein.
Option A: Option A is incorrect. While high-fat meals can delay gastric emptying, which affects the rate of levodopa delivery to the small intestine, dietary fat is not the mechanism of protein-specific wearing-off; the LNAA competition mechanism specifically implicates protein-derived amino acids, not fat.
Option B: Option B is incorrect. Levodopa is not significantly metabolized by hepatic CYP enzymes; it undergoes decarboxylation by AADC and O-methylation by COMT, neither of which is induced by dietary protein intake.
Option C: Option C is incorrect. Peripheral AADC activity is already substantially inhibited by carbidopa, which is taken with levodopa precisely to prevent peripheral conversion; dietary protein does not meaningfully alter peripheral AADC activity.
Option E: Option E is incorrect. While gastric pH can influence drug dissolution for some agents, high-protein meals do not significantly raise gastric pH; the protein-related mechanism of levodopa wearing-off is amino acid transporter competition, not pH-dependent dissolution.
13. A 55-year-old woman with Huntington's disease is started on tetrabenazine for chorea management. Several weeks later, she develops bradykinesia and rigidity consistent with parkinsonism. Which mechanism explains how tetrabenazine causes drug-induced parkinsonism, and how does this differ from antipsychotic-induced parkinsonism?
A) Tetrabenazine blocks postsynaptic D2 receptors, the same mechanism as antipsychotics, but with higher potency
B) Tetrabenazine inhibits dopamine synthesis by blocking tyrosine hydroxylase, while antipsychotics act postsynaptically
C) Tetrabenazine increases dopamine reuptake at the synapse, reducing available dopamine, while antipsychotics block its receptor
E) Tetrabenazine inhibits the vesicular monoamine transporter (VMAT2), depleting presynaptic dopamine stores, while antipsychotics block postsynaptic D2 receptors
ANSWER: E
Rationale:
This question asked you to identify the mechanism of tetrabenazine-induced parkinsonism and contrast it with antipsychotic-induced DIP. Option E is correct. Tetrabenazine causes parkinsonism by blocking the vesicular monoamine transporter type 2 (VMAT2), the transporter responsible for packaging dopamine, serotonin, and norepinephrine into synaptic vesicles for storage and release. VMAT2 inhibition depletes presynaptic monoamine stores, reducing the amount of dopamine available for release into the synapse. With less dopamine available at nigrostriatal synapses, the net effect is dopaminergic deficit and parkinsonism. This mechanism is fundamentally different from antipsychotic-induced DIP, in which the presynaptic dopamine supply is normal but the postsynaptic D2 receptor is pharmacologically blocked, preventing dopamine from acting on its target. Both mechanisms produce parkinsonism, but via opposing sites in the synapse. Reserpine shares the VMAT2 depletion mechanism with tetrabenazine.
Option A: Option A is incorrect. Tetrabenazine does not block postsynaptic D2 receptors; its primary mechanism is presynaptic dopamine depletion via VMAT2 inhibition, which is mechanistically distinct from antipsychotic D2 receptor antagonism.
Option B: Option B is incorrect. Tetrabenazine does not inhibit tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis; its action is on VMAT2-mediated storage, not on biosynthesis.
Option C: Option C is incorrect. Tetrabenazine does not inhibit the dopamine reuptake transporter (DAT); DAT inhibitors include cocaine and amphetamines and would increase rather than deplete synaptic dopamine in the short term.
Option D: Option D is incorrect. Tetrabenazine does not act on presynaptic dopamine autoreceptors; autoreceptor stimulation is the mechanism of action of drugs like apomorphine and has a different pharmacological profile than VMAT2 inhibition.
14. A 60-year-old man develops drug-induced parkinsonism after six months of metoclopramide therapy for gastroparesis. The offending drug cannot be immediately withdrawn due to severe refractory nausea. A medical student suggests adding levodopa/carbidopa to manage the parkinsonian symptoms while continuing metoclopramide. Why is levodopa unlikely to be effective in this situation?
A) The postsynaptic D2 receptor is pharmacologically occupied by metoclopramide, preventing levodopa-derived dopamine from binding and acting at its target
B) Levodopa requires intact presynaptic dopaminergic neurons to be converted to dopamine, which are absent in drug-induced parkinsonism
C) Metoclopramide accelerates levodopa metabolism via CYP1A2 induction, reducing levodopa plasma concentrations below therapeutic levels
D) Levodopa competes with metoclopramide for the large neutral amino acid transporter, preventing adequate CNS penetration when both agents are present
E) Levodopa is only effective in idiopathic Parkinson's disease because drug-induced parkinsonism involves a different receptor subtype
ANSWER: A
Rationale:
This question asked you to explain why levodopa is ineffective in drug-induced parkinsonism caused by a D2 receptor antagonist. Option A is correct. Metoclopramide exerts its parkinsonian effects by blocking postsynaptic D2 receptors in the striatum. When levodopa is administered, it is converted to dopamine in the brain, but that dopamine cannot bind to or activate D2 receptors that are already occupied by metoclopramide. The receptor — the target through which dopamine mediates its antiparkinson effects — is pharmacologically blocked. Providing more dopamine by giving levodopa cannot overcome competitive receptor occupancy at the doses used clinically for gastroparesis. This is why levodopa is generally not a useful treatment for DIP caused by D2 receptor antagonists, and why the correct management approach is to withdraw or substitute the offending drug rather than add levodopa.
Option B: Option B is incorrect. Presynaptic dopaminergic neurons are structurally intact in drug-induced parkinsonism; the nigrostriatal pathway is preserved. Levodopa can indeed be converted to dopamine in the brain — the problem is not with dopamine production but with the blocked receptor.
Option C: Option C is incorrect. Metoclopramide does not significantly induce CYP1A2 or meaningfully reduce levodopa plasma concentrations through enhanced metabolism; this pharmacokinetic interaction is not a recognized mechanism of levodopa failure in DIP.
Option D: Option D is incorrect. While LNAA transporter competition is a real pharmacological interaction affecting levodopa, metoclopramide is not transported by the LNAA transporter and does not compete with levodopa at this site.
Option E: Option E is incorrect. Levodopa does not work through a different receptor subtype in idiopathic PD versus DIP — in both cases it would act through D2 and D1 receptors. The issue is receptor availability, not receptor subtype differences.
15. A 58-year-old immigrant from Eastern Europe develops parkinsonism after years of using a medication prescribed for vertigo and migraine prophylaxis in her home country. The drug is not available in the United States. She has no psychiatric history and has never taken antipsychotics or metoclopramide. Which class of agents is the most likely cause of her drug-induced parkinsonism?
A) Selective serotonin reuptake inhibitors
B) Proton pump inhibitors
C) Calcium channel blockers with dopamine receptor blocking activity
D) Beta-adrenergic antagonists
E) Histamine H1 receptor antagonists
ANSWER: C
Rationale:
This question asked you to identify the class of agents responsible for DIP in a patient using a non-US medication for vertigo and migraine. Option C is correct. Cinnarizine and flunarizine are calcium channel blockers that also possess dopamine D2 receptor blocking activity. They are widely prescribed in many countries outside the United States for vestibular disorders, vertigo, and migraine prophylaxis, and they represent a significant cause of drug-induced parkinsonism internationally — accounting for a substantial proportion of DIP cases in countries where they are available. Their dual mechanism of calcium channel blockade and dopamine receptor antagonism makes them particularly capable of producing parkinsonism at therapeutic doses. They are not available in the United States, which explains why American practitioners may be unfamiliar with them as a cause of DIP.
Option A: Option A is incorrect. Selective serotonin reuptake inhibitors can occasionally cause extrapyramidal symptoms including mild parkinsonism through indirect effects on dopaminergic pathways, but they are not the classic cause of DIP in a patient taking a medication prescribed for vertigo internationally; cinnarizine and flunarizine fit this clinical pattern far more precisely.
Option B: Option B is incorrect. Proton pump inhibitors are not associated with drug-induced parkinsonism; they reduce gastric acid secretion and do not have dopaminergic activity.
Option D: Option D is incorrect. Beta-adrenergic antagonists such as propranolol can cause an action tremor that may superficially resemble parkinsonism, but they do not cause true drug-induced parkinsonism with the full triad of bradykinesia, rigidity, and postural instability.
Option E: Option E is incorrect. First-generation antihistamines with anticholinergic properties can cause sedation and cognitive effects in older adults, but they are not a recognized cause of drug-induced parkinsonism through dopaminergic mechanisms.
16. An 80-year-old man with Parkinson's disease has an eGFR of 35 mL/min. His neurologist is reviewing his antiparkinson regimen. Which of the following agents in the antiparkinson armamentarium most requires dose adjustment or careful monitoring specifically because of reduced renal clearance?
A) Levodopa/carbidopa
B) Selegiline
C) Entacapone
D) Pramipexole
E) Benztropine
ANSWER: D
Rationale:
This question asked you to identify which antiparkinson agent most requires renal dose adjustment in an older patient with reduced kidney function. Option D is correct. Pramipexole is primarily eliminated by renal excretion, with approximately 90% of the dose excreted unchanged in the urine via active tubular secretion. In patients with reduced eGFR, pramipexole clearance is significantly impaired, leading to drug accumulation and increased risk of adverse effects including excessive daytime sleepiness, orthostatic hypotension, hallucinations, and impulse control disorders. Dose reduction is required based on eGFR, with specific dosing adjustments outlined in prescribing information. Ropinirole also requires renal dose adjustment. In an 80-year-old patient with an eGFR of 35 mL/min, careful dose titration and monitoring for dopamine agonist toxicity are essential if pramipexole is used.
Option A: Option A is incorrect. Levodopa/carbidopa does not require significant dose adjustment for renal impairment; levodopa is metabolized by AADC and COMT, with renal excretion playing a minor role in its overall elimination.
Option B: Option B is incorrect. Selegiline undergoes extensive hepatic metabolism; renal clearance of selegiline itself is not the primary elimination pathway, and dose adjustment for renal impairment is not a standard requirement.
Option C: Option C is incorrect. Entacapone is a COMT inhibitor that is almost entirely eliminated by hepatic metabolism and biliary excretion; it does not require renal dose adjustment.
Option E: Option E is incorrect. Benztropine, an anticholinergic agent, undergoes hepatic metabolism, and renal impairment is not the primary concern for its dose adjustment; its main limitation in older adults is anticholinergic toxicity, which is a pharmacodynamic rather than a pharmacokinetic concern.
17. A hospitalist managing a 78-year-old woman with Parkinson's disease and postoperative agitation reaches for the standard delirium protocol, which includes haloperidol. A pharmacist intervenes to prevent a medication error. Which statement correctly identifies the primary reason haloperidol is contraindicated in Parkinson's disease?
A) Haloperidol causes severe orthostatic hypotension that is amplified by the autonomic dysfunction already present in PD
B) Haloperidol blocks striatal D2 receptors, directly antagonizing the dopaminergic tone that antiparkinson therapy is attempting to maintain, causing severe motor worsening
C) Haloperidol is metabolized by the same CYP enzyme as levodopa, producing a dangerous pharmacokinetic interaction that elevates both drug levels
D) Haloperidol causes excessive sedation in PD patients that cannot be reversed with standard measures
E) Haloperidol activates muscarinic receptors in the striatum, compounding the cholinergic-dopaminergic imbalance of PD
ANSWER: B
Rationale:
This question asked you to identify the primary pharmacological reason haloperidol is contraindicated in Parkinson's disease. Option B is correct. Haloperidol is a first-generation antipsychotic that exerts its effects primarily through high-affinity blockade of D2 dopamine receptors. In the striatum, this D2 blockade directly opposes the therapeutic goal of antiparkinson pharmacotherapy, which is to maintain adequate dopaminergic tone at striatal receptors to restore motor function. Blocking D2 receptors in a patient with already-depleted dopaminergic drive produces severe motor worsening — increased rigidity, worsening bradykinesia, postural instability, and dysphagia — that can be life-threatening in advanced PD.
Option A: Option A is incorrect. While haloperidol can contribute to orthostatic hypotension and PD patients do have autonomic dysfunction, orthostatic hypotension is not the primary reason haloperidol is contraindicated; the motor deterioration from D2 blockade is the critical and dominant concern.
Option C: Option C is incorrect. Haloperidol and levodopa are not metabolized by the same CYP enzyme in a way that produces a clinically dangerous pharmacokinetic interaction; levodopa is metabolized by AADC and COMT, not by the CYP system in a manner relevant here. The primary interaction is pharmacodynamic, not pharmacokinetic.
Option D: Option D is incorrect. Excessive sedation is a concern with many CNS-active agents in older PD patients, but sedation alone does not constitute the primary contraindication for haloperidol; the D2 receptor-mediated motor deterioration is the defining danger.
Option E: Option E is incorrect. Haloperidol does not activate muscarinic receptors; it is a D2 antagonist, not a cholinergic agent. Some antipsychotics have anticholinergic properties, which can actually temporarily reduce the cholinergic-dopaminergic imbalance in PD, but this is not the mechanism of the contraindication.
18. An 82-year-old man with Parkinson's disease is taking benztropine for tremor, oxybutynin for overactive bladder, and diphenhydramine for sleep. He presents to clinic with worsening confusion and two recent falls. His daughter reports he seems "foggy" most of the time. Which pharmacological concept best explains the cumulative risk this patient faces from his current medication regimen?
A) Dopaminergic excess from the interaction of multiple central nervous system agents
B) Serotonergic toxicity from simultaneous activation of multiple serotonin receptor subtypes
C) Noradrenergic hyperactivity causing orthostatic instability and attentional dysregulation
D) Dopaminergic deficiency worsened by drug interactions reducing levodopa bioavailability
E) Anticholinergic burden from multiple agents with muscarinic receptor blocking properties, producing cognitive impairment and fall risk
ANSWER: E
Rationale:
This question asked you to identify the pharmacological mechanism underlying the cumulative harm from this patient's medication regimen. Option E is correct. This patient is receiving three agents with significant muscarinic receptor blocking (anticholinergic) activity: benztropine (an anticholinergic antiparkinson agent), oxybutynin (a bladder anticholinergic), and diphenhydramine (a first-generation antihistamine with potent central anticholinergic effects). The concept of anticholinergic burden refers to the cumulative pharmacodynamic load of multiple agents with muscarinic antagonist properties acting simultaneously on the same receptor system. In older adults with Parkinson's disease — who often have already-reduced cholinergic reserve — this cumulative burden produces cognitive impairment, delirium, sedation, and increased fall risk. Anticholinergic burden is a structured medication review priority in every older PD patient at every clinic visit. Each of these drugs individually carries anticholinergic risk; together they represent a potentially dangerous combination.
Option A: Option A is incorrect. The patient's symptoms reflect cognitive suppression and sedation rather than dopaminergic excess; none of the three named agents enhance dopaminergic tone.
Option B: Option B is incorrect. Serotonergic toxicity produces a distinct clinical syndrome including hyperreflexia, clonus, agitation, and autonomic instability; the presentation described here is consistent with anticholinergic burden, not serotonin syndrome.
Option C: Option C is incorrect. Noradrenergic hyperactivity would produce agitation, tachycardia, and hypertension rather than cognitive fogginess and falls; none of the listed agents primarily act through noradrenergic mechanisms.
Option D: Option D is incorrect. None of the three agents — benztropine, oxybutynin, or diphenhydramine — significantly reduce levodopa bioavailability through drug interaction; the symptom burden here is pharmacodynamic, driven by cumulative muscarinic blockade, not a pharmacokinetic reduction in levodopa levels.
19. A 66-year-old woman with Parkinson's disease is started on tolcapone as an adjunct to levodopa/carbidopa for wearing-off control. Which monitoring requirement is mandatory with tolcapone and distinguishes it from entacapone within the COMT inhibitor class?
A) Liver function testing at baseline and at regular intervals during therapy, due to the risk of fatal hepatotoxicity
B) Renal function monitoring every three months, as tolcapone undergoes primary renal elimination
C) Electrocardiogram monitoring for QTc prolongation, as tolcapone prolongs cardiac repolarization
D) Complete blood count monitoring for agranulocytosis, a class effect of COMT inhibitors
E) Serum prolactin measurement, as tolcapone elevates prolactin through dopamine receptor effects
ANSWER: A
Rationale:
This question asked you to identify the specific safety monitoring requirement that distinguishes tolcapone from entacapone. Option A is correct. Tolcapone is associated with rare but potentially fatal hepatotoxicity, including cases of fulminant hepatic failure resulting in death. Because of this risk, tolcapone carries a black-box warning requiring baseline liver function testing followed by monitoring at defined intervals during therapy. Patients must also be informed of the signs and symptoms of hepatic injury and instructed to report them promptly. This mandatory hepatic monitoring requirement differentiates tolcapone from entacapone, which does not carry hepatotoxicity risk and requires no liver function monitoring. Tolcapone is generally reserved for patients who have not responded to or cannot tolerate entacapone, given this additional safety burden.
Option B: Option B is incorrect. Tolcapone is primarily metabolized hepatically and does not require renal function monitoring as a mandatory safety measure; renal elimination is not the primary concern with this agent.
Option C: Option C is incorrect. Tolcapone is not associated with QTc prolongation; cardiac repolarization monitoring is not part of its required safety program.
Option D: Option D is incorrect. Agranulocytosis is not a recognized class effect of COMT inhibitors; this adverse effect is associated with agents such as clozapine and methimazole, not with entacapone or tolcapone.
Option E: Option E is incorrect. Tolcapone does not act on dopamine receptors and does not affect prolactin secretion; prolactin monitoring is not required or clinically relevant for this agent.
20. A 69-year-old man with Parkinson's disease reports that his levodopa works well in the morning and evening but he experiences significant wearing-off and reduced mobility every afternoon, roughly ninety minutes after his main midday meal which typically includes meat, cheese, and eggs. His neurologist recommends a dietary modification. Which strategy is most appropriate to reduce meal-related motor fluctuations?
A) Eliminate all dietary protein and supplement with branched-chain amino acid capsules taken with each levodopa dose
B) Switch from standard levodopa/carbidopa to the extended-release formulation, which is not affected by dietary protein
C) Redistribute daily protein intake so that most protein is consumed in the evening meal, keeping daytime meals low in protein
D) Take levodopa doses with high-carbohydrate snacks to accelerate gastric emptying and improve absorption
E) Increase the levodopa dose at the midday time point by 50% to overcome the competitive inhibition from dietary amino acids
ANSWER: C
Rationale:
This question asked you to identify the dietary strategy that reduces meal-related motor fluctuations caused by protein competition with levodopa. Option C is correct. The protein redistribution diet concentrates the majority of the day's protein intake in the evening meal, when motor function and the need for reliable levodopa effect are typically less critical than during the active daytime hours. By keeping daytime meals — particularly lunch — low in protein, the patient reduces the large neutral amino acid (LNAA) load competing with levodopa for transporter access across the gut wall and blood-brain barrier during the period when good motor control is most needed. This practical dietary strategy can significantly improve daytime levodopa responsiveness without changing the medication regimen.
Option A: Option A is incorrect. Eliminating all dietary protein is nutritionally unsafe and unnecessary; the protein redistribution strategy achieves the clinical goal without risking protein deficiency. Branched-chain amino acid supplementation alongside levodopa would actually worsen LNAA competition, not reduce it.
Option B: Option B is incorrect. Extended-release levodopa/carbidopa does not eliminate the interaction with dietary protein; LNAA transporter competition affects levodopa absorption regardless of formulation, and the protein-redistribution dietary strategy remains relevant even with extended-release formulations.
Option D: Option D is incorrect. High-carbohydrate snacks do not contain amino acids that compete with levodopa and may have some modest benefit on gastric motility, but carbohydrate intake is not the dietary intervention that addresses the LNAA competition mechanism; protein redistribution is the established strategy.
Option E: Option E is incorrect. Increasing the levodopa dose by an arbitrary 50% would increase the risk of peak-dose dyskinesia and does not address the underlying LNAA competition mechanism; dietary protein management is preferable to empiric dose escalation for meal-related wearing-off.
21. A 70-year-old man with Parkinson's disease on rasagiline is admitted for a painful orthopedic procedure. The anesthesiologist considers meperidine for postoperative analgesia. Why is meperidine absolutely contraindicated in this patient?
A) Meperidine is a D2 receptor antagonist that will worsen parkinsonism by blocking striatal dopamine receptors
B) Meperidine is metabolized by MAO-B, and rasagiline blocks this pathway, causing meperidine accumulation and respiratory depression
C) Meperidine competes with levodopa for the large neutral amino acid transporter, reducing CNS dopamine synthesis
D) Meperidine combined with an MAO-B inhibitor can produce a potentially fatal serotonin-like syndrome characterized by hyperthermia, rigidity, and autonomic instability
E) Meperidine prolongs the QTc interval in patients on MAO-B inhibitors due to a pharmacokinetic interaction that elevates both drug levels
ANSWER: D
Rationale:
This question asked you to identify why meperidine is absolutely contraindicated in a patient taking an MAO-B inhibitor. Option D is correct. The combination of meperidine with any MAO inhibitor — including the selective MAO-B inhibitors selegiline and rasagiline used in Parkinson's disease — can produce a potentially life-threatening serotonin-like syndrome. Meperidine has serotonin reuptake inhibiting properties in addition to its opioid agonist activity. When serotonin reuptake is inhibited in the setting of MAO-B inhibition, synaptic serotonin accumulates to toxic levels, producing the clinical syndrome of hyperthermia, severe rigidity, myoclonus, autonomic instability, and altered consciousness. This interaction is one of the most dangerous drug combinations in the antiparkinson pharmacological toolkit and is listed among the ten drug interactions every PD clinician must know. Alternative opioids without serotonergic activity — such as morphine, oxycodone, or fentanyl — should be used instead.
Option A: Option A is incorrect. Meperidine is an opioid agonist acting at mu-opioid receptors; it does not block D2 receptors and does not directly worsen parkinsonism through a dopaminergic mechanism.
Option B: Option B is incorrect. While MAO-B does participate in some aspects of meperidine metabolism, the primary danger of the interaction is not meperidine accumulation causing respiratory depression but rather serotonergic toxicity from the pharmacodynamic interaction.
Option C: Option C is incorrect. Meperidine is not transported by the large neutral amino acid transporter and does not compete with levodopa at this site; this mechanism does not apply to opioids.
Option E: Option E is incorrect. The meperidine-MAO-B inhibitor interaction is pharmacodynamic (serotonergic), not pharmacokinetic; QTc prolongation is not the mechanism of the contraindication for this specific drug combination.
22. A 62-year-old man with schizoaffective disorder develops drug-induced parkinsonism after two years on risperidone. His psychiatric condition requires ongoing antipsychotic therapy — complete discontinuation is not feasible. Which pharmacological strategy offers the best chance of reducing parkinsonian motor symptoms while maintaining adequate psychiatric disease control?
A) Add levodopa/carbidopa to the current risperidone regimen to overcome D2 receptor blockade
B) Switch from risperidone to quetiapine or clozapine, which have minimal D2 receptor affinity at clinical psychiatric doses
C) Add a COMT inhibitor to the regimen to enhance residual dopaminergic tone in the striatum
D) Switch from risperidone to haloperidol, which has a more favorable motor adverse effect profile at low doses
E) Add an anticholinergic agent such as trihexyphenidyl to counteract the dopaminergic deficit caused by risperidone
ANSWER: B
Rationale:
This question asked you to identify the best pharmacological strategy for managing antipsychotic-induced DIP when the antipsychotic cannot be discontinued. Option B is correct. Quetiapine and clozapine are atypical antipsychotics that exert their therapeutic effects predominantly through mechanisms other than high-affinity D2 receptor blockade — they have relatively low D2 receptor affinity at the doses used for psychiatric indications. This low striatal D2 affinity means that switching from a high-affinity D2 antagonist like risperidone to quetiapine or clozapine may allow partial recovery of motor function while maintaining psychiatric disease control. Quetiapine is often preferred first due to the more complex monitoring requirements of clozapine (mandatory blood count monitoring for agranulocytosis). This switch — from high-affinity to low-affinity D2 antagonist — is the established pharmacological strategy for managing DIP when the antipsychotic must be continued.
Option A: Option A is incorrect. Levodopa is generally ineffective in antipsychotic-induced DIP because the D2 receptor is pharmacologically occupied by the antipsychotic agent; adding levodopa provides more dopamine that cannot act at its blocked receptor target.
Option C: Option C is incorrect. COMT inhibitors increase dopamine availability by reducing levodopa degradation, but they require an intact and available D2 receptor system to exert antiparkinson benefit; they are not useful when the receptor is blocked by an antipsychotic.
Option D: Option D is incorrect. Haloperidol is a first-generation antipsychotic with very high D2 receptor affinity — higher than most second-generation agents — and is among the antipsychotics most likely to cause and worsen drug-induced parkinsonism; switching to haloperidol would worsen, not improve, the motor symptoms.
Option E: Option E is incorrect. Anticholinergic agents such as trihexyphenidyl can provide modest symptomatic benefit for DIP by partially rebalancing the striatal cholinergic-dopaminergic equilibrium, but their use in older patients is limited by cognitive adverse effects, and they represent a symptomatic patch rather than the preferred primary strategy; switching to a low-D2-affinity antipsychotic addresses the root pharmacological cause more directly.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.